👆点击查看主席团阵容
2026年4月24日 —— 在全球生物医药创新加速融合与交易模式数字化转型的关键节点，中国生物医药创新领域著名产业生态平台同写意（TONACEA）与博羚资本（Bio-Link Capital）正式达成战略合作。
April 24, 2026 — At a critical juncture of accelerating global biopharmaceutical innovation and the digital transformation of transaction models, TONACEA, a renowned industrial ecosystem platform in China's biopharmaceutical innovation sector, has officially entered into a strategic cooperation with Bio-Link Capital.
双方将秉持“优势互补、生态共建”的原则，共同推进面向全球的生物医药创新协作平台。同写意将发挥其深耕行业二十余年的内容影响力与高端人脉网络，博羚资本将注入其AI驱动的交易与全球化BD（商务拓展）能力，双方致力于连接药企、Biotech、投资机构及科研院所，构建可持续的产业合作新范式。
Guided by the principle of "complementary advantages and ecosystem co-construction," the two parties will jointly advance a global-oriented biopharmaceutical innovation collaboration platform. TONACEA will leverage its content influence and high-end professional network cultivated over two decades, while Bio-Link Capital will inject its AI-driven transaction data and global BD (Business Development) capabilities. Together, they are committed to connecting pharmaceutical companies, biotech firms, investment institutions, and research institutes to build a sustainable new paradigm for industrial cooperation.
此次合作是双方全球化生态布局的关键一步。依托同写意深厚的中国产业整合能力与全链条资源，结合博羚资本在医药资产交易、AI驱动的博羚资产交易平台（https://www.bio-linkcapital.com/contact.html）及跨境BD方面能力，双方共建开放、协同、可扩展的生物医药产业平台，持续释放创新潜力与商业价值。
This cooperation marks a key step in the global ecological layout of both parties. Leveraging TONACEA's profound capabilities in China's industrial integration and full-chain resources, combined with Bio-Link Capital's technological advantages in digitalization of pharmaceutical asset transactions, intelligent valuation, and cross-border BD, the two sides will jointly build an open, collaborative, and scalable biopharmaceutical industrial platform to continuously unleash innovation potential and commercial value.
根据合作协议，双方将在三大核心方向开展深度合作：
In accordance with the cooperation agreement, the two parties will carry out in-depth cooperation in three core areas:
01
品牌活动共建与智库共享
Joint Development of Brand Events and Think Tank Sharing
双方将相互支持对方主办的会议及行业活动。同写意将利用其强大的行业号召力，联合博羚资本打造具有全球影响力的“内容+交易”交流平台。双方将共同发布行业BD交易趋势报告，通过线上直播、国际论坛等多元化场景，提升行业连接效率与品牌价值。
The two parties will mutually support conferences and industry events hosted by each other. TONACEA will utilize its strong industry appeal to jointly build a globally influential "Content + Transaction" exchange platform with Bio-Link Capital. They will jointly release reports on industry BD transaction trends and enhance industrial connectivity efficiency and brand value through diversified scenarios such as online live broadcasts and international forums.
02
资源互通与AI赋能
Resource Interconnection and AI Empowerment
围绕生物医药全产业链，整合科研创新、投融资、全球医药生物资源，博羚资本将开放其AI驱动的项目筛选与匹配系统，为同写意平台上的优质项目提供智能化的价值评估与潜在买家预测；同写意则提供深度的行业洞察与专家网络，共同搭建跨区域、跨领域的生态圈，加速中美产业深度融合。
Centering on the entire biopharmaceutical industrial chain, the two parties will integrate key resources such as scientific research innovation, investment and financing, and CRO/CDMO. Bio-Link Capital will open its AI-driven project screening and matching system to provide intelligent valuation and potential buyer prediction for high-quality projects on the TONACEA platform; TONACEA will provide in-depth industry insights and an expert network to jointly build a cross-regional and cross-field ecological circle, accelerating the in-depth integration of Chinese and U.S. industries.
03
创新药BD出海与Global Deal加速
Innovative Drug BD Global Expansion and Global Deal Acceleration
链接全球MNC（跨国药企）与海外投资机构，构建从项目展示、商务对接、临床开发到商业化落地的一体化加速机制。博羚资本将利用其“Bloomberg终端”式的决策支持能力，助力中国创新药企在BD谈判中争取更优条款，提升高潜力创新资产的全球开发效率，实现从“借船出海”到“造船出海”的跨越。
Linking global MNCs (Multinational Corporations) and overseas investment institutions, the two parties will build an end-to-end acceleration mechanism from project presentation, business matchmaking, and clinical development to commercialization. Bio-Link Capital will leverage its "Bloomberg Terminal-style" decision support capabilities to help Chinese innovative pharmaceutical companies secure better terms in BD negotiations, improve the global development efficiency of high-potential innovative assets, and achieve a leap from "going global by borrowing ships" to "going global by building ships."
同写意创始人及董事长程增江博士表示：
此次合作充分体现了我们‘连接全球生态、赋能生物医药创新增长’的使命。博羚资本在交易数字化领域的探索令人印象深刻，通过与博羚的深度合作，我们共同搭建连接中美市场的关键服务平台，持续创造高质量跨境合作机会，释放产业协同价值。
Dr. Zengjiang Cheng, Founder and Chairman of TONACEA, stated:
This cooperation fully embodies our mission of 'Connecting the Global Ecosystem and Empowering Biopharmaceutical Innovation and Growth'. Bio-Link Capital's exploration in the field of transaction digitalization is impressive. Through in-depth cooperation with Bio-Link Capital, we will build a key service platform connecting the Chinese and U.S. markets, continuously create high-quality cross-border cooperation opportunities, and release industrial synergy value.
博羚资本（Bio-Link Capital）CEO陈锋表示：
同写意是中国生物医药创新的风向标，拥有最深厚的行业积淀。博羚资本致力于成为医药界的‘Bloomberg终端’，我们不仅提供交易场所，更提供深度决策支持。此次携手同写意，是将我们的AI算法与数据能力植入到中国最活跃的创新生态中，帮助更多中国Biotech在资本寒冬中找到确定的出海路径，让好资产卖出好价格。
CEO of Bio-Link Capital KEN stated:
TONACEA is a leading indicator of China's biopharmaceutical innovation, possessing the deepest industry accumulation. Bio-Link Capital is committed to becoming the 'Bloomberg Terminal' of the pharmaceutical industry; we provide not just a trading venue, but deep decision support. This partnership with TONACEA involves embedding our AI algorithms and data capabilities into China's most active innovation ecosystem, helping more Chinese biotechs find a definite path to global expansion amidst the capital winter, and ensuring good assets command good prices.
作为合作重要落地，博羚资本将在**首届大国新药全球会议（CPIC 2026）**设立专属专场，聚焦中国企业项目转让出海、海外企业与投资机构重点关注的领域与项目，搭建精准高效的跨境对接桥梁。
As a key implementation of the cooperation, Bio-Link Capital will host a dedicated session at the inaugural China Pharmaceutical Innovation Conference (CPIC 2026), focusing on overseas transfer of projects from Chinese enterprises, as well as fields and projects of key interest to overseas enterprises and investment institutions, to build a precise and efficient cross-border matchmaking bridge.
关于博羚资本
博羚资本（Bio-Link Capital）致力于构建全球领先的医药资产交易与权益交易平台（https://www.bio-linkcapital.com/contact.html）。依托AI驱动的大数据分析与深厚的行业资源，博羚资本为生物医药企业提供从BD交易策略、智能估值、跨境对接到投融资咨询的一站式服务，旨在消除信息不对称，提升全球医药资源配置效率。
ABOUT Bio-Link Capital
Bio-Link Capital is committed to building a world-leading platform for pharmaceutical asset transactions and equity trading. Relying on AI-driven big data analysis and deep industry resources, Bio-Link Capital provides biopharmaceutical companies with one-stop services ranging from BD transaction strategy, intelligent valuation, and cross-border matchmaking to investment and financing consulting, aiming to eliminate information asymmetry and improve the efficiency of global pharmaceutical resource allocation.
关于同写意
同写意是中国生物医药创新领域的著名生态平台，深耕中国新药创制20余年，已发展为推动中国医药创新力量的关键平台组织，成为链接跨国药企和本土创新的核心枢纽。
同写意聚跨国药企、Biotech公司、投资机构、科研院所及监管专家，构建起覆盖研发全链条的高端人脉网络与知识共享体系。业务涵盖行业峰会、技术论坛、企业定制培训、媒体传播及战略咨询，在北京、上海、苏州、广州、深圳等地设有分支机构，形成辐射全国的运营网络。
同写意微信公众号与视频号持续输出深度行业研究，观点被资本与媒体高频引用，成为业界公认的“官方信源”。平台联合发布的“华山奖”，树立中国创新药国际化标杆，推动本土企业走向世界舞台。
About TONACEA
TONACEA is a premier ecosystem platform in China's biopharmaceutical innovation sector. With over 20 years of deep commitment to advancing China's novel drug development, it has evolved into a key organizational force driving the country's pharmaceutical innovation, serving as a core hub connecting multinational pharmaceutical companies with local innovation.
TONACEA brings together multinational pharmaceutical companies, biotech firms, investment institutions, research institutes, and regulatory experts, establishing a high-end professional network and knowledge-sharing ecosystem that spans the entire R&D value chain. Its business scope encompasses industry summits, technical forums, customized corporate training, media communications, and strategic consulting. With branches in Beijing, Shanghai, Suzhou, Guangzhou, Shenzhen, and other cities, TONACEA has built a nationwide operational network.
The TONACEA WeChat official account and video channel consistently deliver in-depth industry insights, with its perspectives frequently cited by investors and media, earning recognition as a trusted "authoritative source" within the industry. The "Huashan Award," co-launched by the platform, sets a benchmark for the globalization of Chinese innovative drugs and empowers local enterprises to step onto the world stage.
扫码立刻报名
早鸟票限时6折抢购!!
// 大会框架//
CPIC主会场
✓ 中国新兴支柱产业的全球坐标
✓ 全球生物医药创新前沿
✓ 中国药企的MNC之路
✓ FIC与世界级药物开发
✓ 创新药中国效率与持续进化
✓ CPIC成果发布
✓ CPIC荣耀颁奖
中国创新药前沿技术
✓ CNS创新药开发会议
✓ 细胞药物与ATMP会议
✓ 体内CAR-T创新专场
✓ 基因治疗与罕见病药物开发会议
✓ 小核酸药物创新会议
✓ mRNA与疫苗会议
✓ TCE与新型抗体药物会议
✓ 干细胞与再生医学新技术会议
✓ 偶联药物创新会议
✓ 新分子实体药物研发会议
✓ 分子胶与Protac会议
✓ 类器官与生物芯片会议
✓ 创新核药会议
✓ GLP-1与减肥新药会议
✓ 生物类似药开发会议
✓ AI与药物发现会议
药政法规与药品监管
✓ 欧美新药审评审批趋势会议
✓ 818号令与生物医学新技术转化应用会议
✓ 828号令与中国药品注册提速会议
✓ 中美药品注册合规会议
✓ 医疗器械全球注册法规会议
知识产权与法律
✓ 生物医药知识产权战略与策略会议
✓ 新药出海法律专题会议
✓ 新药出海与跨境交易争议解决会议
药品生产与供应链管理
✓ 生物药分段生产实践会议
✓ 数字化工厂与智能制造会议
✓ 生物药上游供应链会议
✓ 生物药分离纯化会议
✓ 冷链物流管理会议
医工融合与创新医疗器械
✓ 脑机接口专场会议
✓ 学院院长与医院院长会议
✓ 创新医疗器械会议
✓ 生物医学新材料开发会议
中国创新生态与创新模式
✓ 传统药企创新转型会议
✓ 生物医药园区生态建设会议
✓ 科研转化与早期项目孵化会议
✓ CRO/CDMO进化会议
✓ 利用外部合作加速创新会议
✓ 从研发故事到盈利故事
✓ 生物医药ESG建设会议
投融资与企业上市和并购
✓ IPO的监管与上市路径会议
✓ 跨境融资与美元基金布局会议
✓ NewCo的进化与超越会议
✓ RWA作为新的融资工具会议
✓ 银行支持创新药/械会议
✓ 生物医药企业并购会议
✓ 项目路演专场会议
跨境合作与中国新药出海
✓ BD出海的进阶与生态重构
✓ 创新药全球品牌建设与市场推广
✓ 新药商业化出海会议
✓ 东南亚合作专场会议
✓ 中新合作专场会议
✓ 香港的全球化机遇会议
✓ 中欧合作专场会议
✓ 中日合作专场会议
✓ 中韩合作专场会议
✓ 中美合作专场会议
人力资源建设
✓ 医药BD团队搭建与全球项目拓展会议
✓ 创新人才战略与团队建设会议
✓ 科学家创业研讨会议
✓ 投资人创业会议
1v1约见会议
企业/机构冠名专场会议
✓ 机构冠名专场会议
✓ 校友会专场
✓ 行业协会专场
晚会与社交活动
✓ 同写意之夜
✓ 社交酒会
✓ 主题午餐会
✓ 灵魂美学艺术鉴赏会
✓ 10公里城市跑
✓ 高尔夫球会
✓ 走访生物医药园区
✓ 国外嘉宾会后观光游览
更多社交活动......
// 注册报名//
扫码立刻报名
早鸟票限时6折抢购!!
// 报告/路演征集 //
大会将征集报告/路演，报告时长15min，路演时长8min。
// 专题策划人征集//
大会征集圆桌对话主题及对话召集人，每场时长约40min。
// 展商及支持机构征集 //
大会特设10000㎡专业展厅，用于企业/机构品牌展示与交流洽谈。
// 会议咨询//
同写意：010-83634390/83634290
邮 箱：txy@cpic-shanghai.com
官 网：www.cpic-shanghai.com
领英官方账号：CPIC China
报名咨询
赵雅娴：19910727558
丁杰逸：19910274182
翁 琦：17751479618
商务合作
李佳媛：17718589627
李 珍：13522802756
张明玥：15101686528
宁园园：18710112302
刘 杨：18010079080
杨云停：17365430165
媒体合作
李 纯：19910611152
首届大国新药全球会议（CPIC）相关链接
(上下滑动查看更多）
卷上天”的PD-1/VEGF，下一个BD机会在哪里？
CPIC 2026｜Overseas Registration Now Open
CPIC 2026丨中国Biotech研产销一体化VS专业分工
CPIC 2026 | 招募！青年菁英同行计划正式启动
CPIC 2026丨同写意与NAPPA正式签署战略合作协议
818号令：谁被挡在门外？
CPIC 2026 | 中日健康产业合作专场
CPIC 2026 | 四家机构成为大会指导单位
CPIC 2026丨优艺生物专场：先进干细胞培养工艺
中国创新药，开始批量赚钱了
CPIC 2026丨优艺生物专场：先进干细胞培养工艺
生物医学新技术变天：新规下的生与死
CPIC 2026丨同写意与BioCentury达成合作协议
CPIC 2026丨1V1预约洽谈系统正式启用！
CPIC 2026丨专场对话：借力中国创新，加速全球药物研发进程
《金融时报》：减肥药战争，进入中国时区
一场万亿“灰市”的转正风暴
专访加科思王印祥：从Revolution逆袭，看中国Biotech的启示
药价改革新政落地，创新药迎来“价值回归”
CPIC 2026｜首届大国新药全球会议官网正式启用
默沙东，高攀不起？
口服大环肽，悄悄火了
CPIC 2026丨同写意与GB·Partner正式签署战略合作协议中国创新药企的“肉身出海”
CPIC 2026丨艾里奥斯专场：共建生物制药供应链创新合作生态
CPIC 2026 | 首届大国新药全球会议主席团成立！
CPIC 2026丨艾里奥斯专场：共建生物制药供应链创新合作生态
创新药的黄金航道，起风了
CPIC 2026丨香港中华工商总会与香港生物医药创新协会携手，共启大国新药新篇章
ADC下半场，中国新药还有什么牌？
CPIC 2026丨Protheragen专场：全球生物医药跨境交易
CPIC 2026 | 首届"大国新药"全球会议LOGO发布
中国原创“核”力崛起
A+H，中国biotech加速“双栖”
CPIC 2026丨龙心DRAGONHEART携灵魂美学赋能，共筑大国新药文化底色
中国新药，重回并购场
CPIC 2026 | 首届大国新药全球会议早鸟票限时抢购！
中国创新药，掀起“头对头”试验风暴
特朗普征税100%背后：锁不住的中国新药
中国创新药出海，从“年度繁荣”到“季度爆发”
华尔街资本，瞄准中国Biotech
NewCo迎来变现时刻
礼来狂砸28亿背后：中国创新药企上桌
一个张江“老药谷人”，与他亲历的中国创新药二十年
CPIC 2026丨君联资本 & Rxilient专场：医药企业全球化发展与新兴市场合作
AI制药，迎来“中国时刻”
创新东移，监管何从？
跨国药企集体“加仓”中国
两天内80亿并购：中国创新药，正成为全球“硬通货”
中国药企“叫板”全球最贵
Blueprint Unveiled: The 1st CPIC to Build China’s Answer to the J.P. Morgan Healthcare Conference
首届CNS创新药研发会议来了丨CPIC全球会议
大会蓝图发布！首届大国新药全球会议打造中国版JPM
港股IPO，红筹架构的“守与破”
朱迅：中国创新药，该从“研发故事”切换到“盈利故事”了
定档7.22-24，首届大国新药全球会议（CPIC）定位“四叶草”
当银行的钱，涌入创新药
大国新药必将成就新药大国
点击 "阅读原文"，立即访问CPIC官网
